You are here: Industry Insights > Market News

Market News

HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress ACN Newswire
April 25, 2025
HighTide Therapeutics announced that it will present at the EASL Congress 2025. The presentations include New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010).
InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China PharmaSources
April 27, 2025
InnoCare Pharma announced that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) for the first-line treatment of patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for CLL/SLL Patients in China PharmaSources
March 28, 2025
InnoCare announced the first patient dosed in the Phase III trial of ICP-248 combined with orelabrutinib for CLL/SLL. It's a potential treatment, with other trials advancing.
InnoCare Releases 2024 Results and Business Highlights PharmaSources
March 27, 2025
InnoCare announced 2024 annual results, including financials, R&D progress in oncology and autoimmune diseases, and globalization efforts.
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China PharmaSources
March 20, 2025
InnoCare announced the first patient dosing in the Phase III trial of ICP - 488 for psoriasis. It showed good results in Phase II, aiming to meet unmet needs.
Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD PharmaSources
March 11, 2025
InnoCare Pharma; TYK2 inhibitor ICP - 488; psoriasis; 2025 AAD Annual Meeting; clinical data
InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China PharmaSources
February 18, 2025
InnoCare Pharma announced on Feb. 17, 2025 that CDE approved the Phase III trial of ICP - 248 combined with orelabrutinib for first - line CLL/SLL treatment in China.
TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients' Access to Life-Changing Medicines PR Newswire
February 12, 2025
Partnership taps real-world data to accelerate clinical trials and drug development in Japan.
Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases PharmaSources
October 15, 2024
Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.
Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization PharmaSources
October 15, 2024
Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today the appointment of Dr. Elisabeth Lackner to its Supervisory Board.